Intelligence / Healthtech / New Clinical Trials / Basilea Pharmaceutica
Basilea Pharmaceutica
4 Nov 2026: Trial registered · A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 4 Nov 2026
- Title
- A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
- Conditions
- End Stage Renal Disease on Dialysis, Adult
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- United States
- Country
- United States
- Reference
- NCT07916181
- Location
- United States
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Basilea Pharmaceutica
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from United States
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.